No­vo Nordisk’s block­buster GLP-1 prod­ucts Ozem­pic and We­govy are among the next 15 drugs sub­ject to the gov­ern­ment’s Medicare ne­go­ti­a­tion pro­gram un­der the In­fla­tion Re­duc­tion Act, fol­low­ing re­peat­ed calls from law­mak­ers to make the treat­ments more af­ford­able...